Gelonghui on November 8th | guangdong zhongsheng pharmaceutical announced that its wholly-owned subsidiary Guangdong Southern Pharmaceutical Group Co., Ltd. recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for the carmosmond solution for oral administration. Carmosmond oral solution is used to treat patients with thick sputum and difficulty sputum expectoration caused by chronic bronchitis, bronchial asthma, and other diseases. It is a Category B drug in the national essential drug list and medical insurance catalog.